Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer

• Published in: Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi Vol. 115; no. 1; p. 163
• Main Authors: Dumache, Raluca, David, Dana, Kaycsa, Adriana, Minciu, R, Negru, S, Puiu, Maria
• Format: Journal Article
• Language: English
• Published: Romania 01.01.2011
• Subjects: Biomarkers, Tumor - genetics; Cadherins - genetics; Chromosome Aberrations; DNA Methylation - genetics; Early Detection of Cancer; Epigenesis, Genetic; Genes, p53 - genetics; Humans; Monitoring, Physiologic; Neoplasm Invasiveness; Neoplasm Recurrence, Local - prevention & control; Prognosis; Quality of Life; Risk Assessment; Urinary Bladder Neoplasms - diagnosis; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - therapy
• ISSN: 0048-7848

Urinary bladder cancer is the fifth most common cancer in the Western world and is responsible for about 3% of all cancer-related deaths. Because most advanced invasive or metastatic cancers have low cure rates, risk assessment and early detection of the clinically occult premalignant phases of neoplasia are a particular importance. Many tumor biomarkers for bladder cancer have been evaluated for use in detecting and monitoring bladder cancers tissue specimens, bladder washes, and urine specimens but, none of the biomarkers reported to date has shown sufficient sensitivity and specificity to detect the entire spectrum of bladder cancers in routine clinical practice. The limitations of established prognostic markers requires us to identify better molecular parameters that could be of interest in predicting the prognosis of bladder cancer patients, in particular, the high-risk patient groups that are at risk of progression and recurrence. Methylation is an important molecular mechanism in the development of bladder cancer and could be used as a prognostic and diagnostic biomarker, because hypermethylation of several gene promoters was detected in urine sediment DNA from bladder cancer patients. Aberrant patterns of epigenetic modification could be, in the near future, crucial indicators in cancer diagnosis, prognosis, and additionally could be good targets for developing novel therapies while maintaining quality of life.